

VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity!

<https://marketpublishers.com/r/VF1E8B027EBEN.html>

Date: October 2011

Pages: 4

Price: US\$ 90.00 (Single User License)

ID: VF1E8B027EBEN

Abstracts

Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients and gain greater HCV market through shorter duration and dosing advantage to a niche pts population of IL28B CC Genotype. We expect most of the near term milestones related to Earnings, Rheumatoid Arthritis (RA), Cystic Fibrosis (CF), etc. programs to have a positive impact on the stock price. For more details, please read our report released on 25th October, 2011 on VRTX titled “HCV/HIV Co-Infection – An Untapped Opportunity!”

Contents

COMPANIES MENTIONED

VERTEX

I would like to order

Product name: VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity!

Product link: <https://marketpublishers.com/r/VF1E8B027EBEN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VF1E8B027EBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970